Intrathecal And Intracerebroventricular Drug Delivery is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Intrathecal (IT) and intracerebroventricular (ICV) drug delivery are targeted delivery methods that bypass the blood-brain barrier (BBB) by placing therapeutic agents directly into the cerebrospinal fluid (CSF) spaces.[1][2] These approaches are essential for treating neurological disorders where systemically administered drugs cannot achieve therapeutic concentrations in the central nervous system (CNS). Intrathecal delivery involves injection into the subarachnoid space surrounding the spinal cord, while intracerebroventricular delivery involves injection directly into the cerebral ventricles.[1:1]
These delivery methods have become increasingly important in neurodegenerative disease therapeutics, particularly for large molecule drugs (antisense oligonucleotides, proteins, antibodies), gene therapies, and small molecules that do not cross the BBB effectively.[3] The ability to deliver drugs directly to the CSF dramatically increases CNS exposure while reducing peripheral exposure and associated toxicities.
The CSF system consists of approximately 150 mL of fluid in adults, distributed among the cerebral ventricles (approximately 25 mL), the cranial subarachnoid space (approximately 100 mL), and the spinal subarachnoid space (approximately 25 mL).[4] CSF is produced by the choroid plexus at a rate of approximately 500 mL per day, circulating through the ventricular system and subarachnoid spaces before being absorbed into the venous system through arachnoid villi.
Understanding CSF dynamics is critical for drug delivery:
The blood-CSF barrier (BCSFB) consists of choroid plexus epithelial cells connected by tight junctions, separating the CSF from blood capillaries.[2:1] Unlike the BBB, the BCSFB has limited expression of efflux transporters, but still restricts passage of most large molecules and many small molecules.
Intrathecal and ICV delivery bypass both the BBB and BCSFB, achieving direct access to the CNS extracellular space. However, distribution from the CSF to brain parenchyma remains limited by:
Drug distribution from the CSF to CNS tissue is influenced by:
The most common method for intrathecal delivery involves lumbar puncture (LP), typically performed at the L3-L4 or L4-L5 vertebral level to avoid spinal cord injury.[5]
Procedure:
Advantages:
Limitations:
For chronic delivery, implanted systems provide reliable access:
Components:
Pump types:
Applications:
ICV delivery involves access to the cerebral ventricles, typically the lateral ventricle:
Methods:
Advantages over intrathecal:
Limitations:
Convection-enhanced delivery (CED) uses hydrostatic pressure to drive drug directly into brain tissue, bypassing CSF altogether:[8]
CED is particularly relevant for:
ASOs are short synthetic oligonucleotides that modulate RNA splicing, translation, or degradation. Several ASOs have received FDA approval for neurological diseases, all administered intrathecally:[3:1]
| Drug | Disease | Target | FDA Status |
|---|---|---|---|
| Nusinersen | Spinal Muscular Atrophy | SMN2 | Approved (2016) |
| Inotersen | hATTR Polyneuropathy | TTR | Approved (2018) |
| Tominersen | Huntington's Disease | HTT | Phase 3 (2021) |
| IONIS-HTTRx | Huntington's Disease | HTT | Phase 1/2 |
Dosing: Typically loading dose followed by maintenance doses every 1-3 months
Distribution: Achieves widespread CNS distribution within weeks of repeated dosing[9]
Intrathecal and ICV routes are being developed for CNS gene therapy:
AAV vectors: Adeno-associated viruses can be delivered intrathecally to achieve broad CNS transduction:[10]
Challenges:
For lysosomal storage diseases affecting the CNS:
| Enzyme | Disease | Delivery Route | Status |
|---|---|---|---|
| Idursulfase | Hunter Syndrome (MPS II) | IT (clinical trials) | Phase 2/3 |
| Arylsulfatase A | Metachromatic Leukodystrophy | IT (preclinical) | Preclinical |
| Hexosaminidase A | Tay-Sachs | ICV (preclinical) | Preclinical |
Some small molecules that poorly cross the BBB may be delivered intrathecally:
Therapeutic antibodies are typically too large to cross the BBB. Intrathecal delivery is being explored for:
Early clinical trials show limited efficacy, likely due to insufficient distribution from CSF to brain parenchyma.[11]
Key parameters for intrathecal drug delivery:
Although intrathecal delivery bypasses the BBB, systemic exposure still occurs:
Minimizing systemic exposure is important for drugs with peripheral toxicity.
Intrathecal doses are typically 1-10% of equivalent intravenous doses due to:
Lumbar Puncture:
Implanted Systems:
ASOs:
Gene Therapy:
Research focuses on improving drug distribution from CSF to brain:
Other CNS delivery approaches under development:
Future approaches may include:
Ideal candidates for intrathecal delivery:
Key monitoring parameters:
Successful intrathecal therapy requires:
Intrathecal and intracerebroventricular drug delivery provide essential routes for treating CNS diseases that cannot be effectively addressed with systemic therapy. These approaches are particularly important for large molecule drugs (ASOs, proteins, antibodies), gene therapies, and select small molecules. While delivery methods continue to improve, challenges remain in achieving uniform drug distribution throughout the CNS. Understanding CSF dynamics, selecting appropriate delivery methods, and managing complications are essential for optimal clinical outcomes.
The study of Intrathecal And Intracerebroventricular Drug Delivery has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Rigo et al. Antisense oligonucleotide-based therapies for diseases of the nervous system (2020). Nature Reviews Drug Discovery. 2020. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Geary et al. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides (2015). Advanced Drug Delivery Reviews. 2015. ↩︎ ↩︎ ↩︎
Bennett et al. RNA-targeted therapeutics for neurological disease (2019). Drug Discovery Today. 2019. ↩︎ ↩︎
Sakka et al. Physiology and pathophysiology of the cerebrospinal fluid (2011). Journal of Neurology. 2011. ↩︎ ↩︎
Evans, Lumbar puncture technique (2018). Neurologia. 2018. ↩︎ ↩︎ ↩︎
De Andres et al. Intrathecal drug delivery systems (2020). International Journal of Molecular Sciences. 2020. ↩︎ ↩︎
Morrison et al. Intracerebroventricular drug delivery (2014). Neuropharmacology. 2014. ↩︎
Bobo et al. Convection-enhanced delivery (1994). Proceedings of the National Academy of Sciences. 1994. ↩︎ ↩︎
Evers et al. Target engagement with antisense oligonucleotides (2015). Trends in Pharmacological Sciences. 2015. ↩︎ ↩︎
Samaranch et al. AAV9-mediated CNS gene therapy (2014). Molecular Therapy. 2014. ↩︎ ↩︎ ↩︎
Sevigny et al. Antibody therapy for Alzheimer's disease (2016). Nature. 2016. ↩︎
Pardridge, Drug delivery to the brain (2021). Drug Discovery Today. 2021. ↩︎